09:30 AM EST - Aeterna Zentaris Inc. : Provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals, for the potential treatment of Parkinson’s Disease. AIM Biologicals are targeted, highly specific autoimmunity modifying therapeutics. The scientific concept behind this platform technology is “feto-maternal-tolerance”. During pregnancy, the immune system of mothers does not attack the fetus, which consists of 50% paternal proteins. For this, the immune system is not downregulated, but selectively de-sensibilized, thus ensuring that the mothers continue to be protected against infections Aeterna Zentaris Inc.
shares T.AEZS are trading unchanged at $0.32.
